Related Experiment Videos
Future challenges in the clinical development of thymidylate synthase inhibitor compounds
1Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA.
Abstract:
Thymidylate synthase (TS) is a folate-dependent enzyme that plays a critical role in providing the thymidylate nucleotide precursors essential for DNA biosynthesis. Given the increased metabolic demands that accompany malignant cell proliferation, it has been well-appreciated that TS represents an important target for cancer therapy. The fluoropyrimidines were the first class of agents to be directed against TS. As a result of extensive preclinical and clinical investigations, new inhibitor compounds of TS were subsequently designed and developed. This class of antifolate analogues includes ZD1694 (Tomudex), LY231514 (MTA), BW1843U89, ZD9331, AG331, and AG337. Although each of these analogues acts to inhibit TS, the data from both preclinical and early clinical studies suggest that they may each have a different spectrum of tumors against which they are active. In this commentary, an update of the current status of TS inhibitor compounds is presented. Finally, the future challenges that lie ahead in the clinical development with specific focus on identifying those critical factors that will determine the spectrum of antitumor activity and therapeutic selectivity of this interesting class of compounds are discussed.
Insights
New antifolate analogues targeting thymidylate synthase (TS) show promise for cancer therapy. Further research is needed to identify factors determining their antitumor activity and selectivity.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- Thymidylate synthase (TS) is crucial for DNA synthesis and a key target in cancer therapy.
- Fluoropyrimidines were the first agents targeting TS, leading to the development of new antifolate analogues.
- Malignant cell proliferation increases metabolic demands, highlighting TS as a critical therapeutic target.
Purpose of the Study:
- To provide an update on the current status of thymidylate synthase inhibitor compounds.
- To discuss future challenges in the clinical development of TS inhibitors.
- To identify factors influencing the antitumor activity and therapeutic selectivity of TS inhibitors.
Main Methods:
- Review of preclinical and clinical investigations of TS inhibitor compounds.
- Analysis of data from early clinical studies on various antifolate analogues.
- Discussion of challenges in clinical development and therapeutic selectivity.
Main Results:
- Several new antifolate analogues targeting TS have been developed, including ZD1694, LY231514, BW1843U89, ZD9331, AG331, and AG337.
- Preclinical and early clinical data suggest varying antitumor activity spectra for these analogues.
- Each analogue inhibits TS but may exhibit different efficacy across tumor types.
Conclusions:
- Antifolate analogues targeting thymidylate synthase represent a promising class of anticancer agents.
- Identifying critical factors for antitumor activity and therapeutic selectivity is essential for future clinical development.
- Further research is needed to optimize the use of these TS inhibitors in cancer therapy.